Table 2.: Trials Comparing Natural and Protein-Containing Synthetic Surfactants

Year Authors Surfactants Used Participants Endpoints of Trial Results of Trial
2005 Sinha et al. [44]
(STAR trial)
  1. Lucinactant
  2. Poractant
 252
24-28 weeks GA
  1. Pneumothorax
  2. IVH
  3. Mortality rate
 Lucinactant reduced mortality rate
No difference in other endpoints
2005 Moya et al. [43]
(SELECT trial)
  1. Lucinactant
  2. Beractant
 867
24-32 weeks GA
600-1250g
  1. Short-term outcome
  2. Pneumothorax
  3. RDS rate
  4. Mortality-related to RDS
 Lucinactant reduced short-term outcome, RDS rate, and RDS-related mortality, but not pneumothorax and other morbidities

Short-term outcome: O2 requirement, duration of O2 treatment, duration of mechanical ventilation, RDS after dosing with surfactant.